820 Assessing CIN2+ risk in cytology-negative, non-16–18 high-risk HPV individuals

Introduction/Background The 2019 ASCCP(American Society of Colposcopy and Cervical Pathology) guideline advises a risk-based follow-up approach for non-16–18 HR HPV-positive patients, relying on previous results. Regional variations in CIN2+ lesions incidence may stem from diverse distributions of non-16–18 HR-HPVs. Debate surrounds the follow-up plan for these patients. This study aims to explore the link between non-16–18 HR HPV and CIN2+ lesions. Methodology Our study retrospectively reviewed 679 patients who attended Hacettepe University Hospital between August 2018, and February 2023, and underwent colposcopy. Patients with insufficient cytology or reported as ASC (Atypical Squamous Cells) or higher were excluded from the study Results Out of the 679 patients included in the study, 387 (57%) underwent colposcopy-guided biopsy. Among these biopsies, 314 (81%) showed benign pathologies, while 40 (10.3%) had CIN1, 9 (2.3%) had CIN2, 21 (5.4%) had CIN3, and 3 (0.8%) were reported as carcinoma. HR-HPV positivity was present in 407/679 (59.9%) of the patients included in the study. Colposcopy was performed in patients with the indications of HR-HPV positivity, postcoital bleeding and suspicion of cervical lesion. Colposcopic biopsy was performed in 248/407 (60.9%) of HR-HPV positive patients (table-1). The detection rate for CIN2+ lesions associated with HPV 16 and 18 was 9.2%, while the rate of these lesions in non-16,18 HR HPVs was 3.6% (p=0.79). Among CIN2+ lesions, 71.9% tested positive for HPV 16, whereas no patients showed HPV 18 positivity. In the study cohort, 25.5% (173 out of 679) tested positive for non-16–18 HR-HPV. Among these cases, HPV 31 appeared most frequently in CIN 2+ lesions (37.5%), followed by HPV 53 at 25%, while HPV 33, 52, and 58 were each found in 12.5% of cases. Conclusion Region-specific assessments within non-16–18 HR-HPV subgroups can identify high-risk CIN 2+ probabilities, enabling customized follow-up and treatment approaches for each nation. Disclosures There is no conflicts of interest in this study.